A detailed history of Long Focus Capital Management, LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Long Focus Capital Management, LLC holds 12,346,417 shares of ADAP stock, worth $11.7 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares
12,346,417
Previous 10,684,233 15.56%
Holding current value
$11.7 Million
Previous $16.9 Million 28.33%
% of portfolio
0.49%
Previous 0.91%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.83 - $1.47 $1.38 Million - $2.44 Million
1,662,184 Added 15.56%
12,346,417 $12.1 Million
Q1 2024

May 14, 2024

SELL
$0.7 - $1.75 $981,877 - $2.45 Million
-1,402,682 Reduced 11.6%
10,684,233 $16.9 Million
Q4 2023

Feb 14, 2024

BUY
$0.43 - $0.79 $483,215 - $887,768
1,123,757 Added 10.25%
12,086,915 $9.55 Million
Q3 2023

Nov 14, 2023

BUY
$0.73 - $1.04 $2.3 Million - $3.28 Million
3,150,630 Added 40.33%
10,963,158 $8.55 Million
Q2 2023

Aug 14, 2023

BUY
$0.9 - $1.51 $2.14 Million - $3.59 Million
2,377,089 Added 43.73%
7,812,528 $7.19 Million
Q1 2023

May 17, 2023

BUY
$1.06 - $2.16 $2.82 Million - $5.75 Million
2,662,648 Added 96.03%
5,435,439 $5.92 Million
Q1 2023

May 12, 2023

SELL
$1.06 - $2.16 $2.66 Million - $5.42 Million
-2,510,848 Reduced 47.52%
2,772,791 $3.02 Million
Q4 2022

Feb 13, 2023

BUY
$1.05 - $2.53 $518,856 - $1.25 Million
494,149 Added 10.32%
5,283,639 $7.71 Million
Q3 2022

Nov 14, 2022

BUY
$1.06 - $2.41 $116,598 - $265,097
109,999 Added 2.35%
4,789,490 $5.15 Million
Q2 2022

Aug 12, 2022

BUY
$1.33 - $2.28 $332,500 - $570,000
250,000 Added 5.64%
4,679,491 $7.96 Million
Q1 2022

May 13, 2022

BUY
$1.73 - $4.06 $3.92 Million - $9.2 Million
2,267,178 Added 104.85%
4,429,491 $9.13 Million
Q4 2021

Feb 14, 2022

BUY
$3.5 - $5.68 $7.57 Million - $12.3 Million
2,162,313 New
2,162,313 $8.11 Million

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $155M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Long Focus Capital Management, LLC Portfolio

Follow Long Focus Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Long Focus Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Long Focus Capital Management, LLC with notifications on news.